Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 3:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 207 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Early Alzheimer´s Disease
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 85 more
Terminated Phase 2 Interventional Results available

Phase IIa L-serine Trial for eAD

NCT03062449
Conditions
Alzheimer Disease
Interventions
L-Serine, Placebo Gummy
Drug · Other
Lead sponsor
Aleksandra Stark
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Completed Not applicable Interventional Accepts healthy volunteers

EPIC: An Intervention for Early-stage AD Dyads - Adapted for Virtual Delivery

NCT03144921
Conditions
Dementia, Alzheimer Disease, Memory Loss
Interventions
psychoeducational skills training intervention
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Dementia, Alzheimers Disease
Interventions
Not listed
Lead sponsor
Corewell Health East
Other
Eligibility
60 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Completed No phase listed Observational Accepts healthy volunteers

Early Markers of Cognitive Change and Alzheimer s Disease

NCT01867346
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
2,850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Results available

Nicotinamide as an Early Alzheimer's Disease Treatment

NCT03061474
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Nicotinamide, Placebo Comparator
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Irvine, California • Los Angeles, California
Conditions
Alzheimer Disease
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
185
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 146 more
Conditions
Early Alzheimer's Disease
Interventions
E2609
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Conditions
Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Enrolling by invitation Not applicable Interventional

TMS Pilot in Early AD II

NCT06817902
Conditions
Alzheimer Disease
Interventions
Intermittent theta burst stimulation active coil, Sham coil
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
40 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Alzheimer Disease
Interventions
PQ912, Placebo
Drug · Other
Lead sponsor
Vivoryon Therapeutics N.V.
Industry
Eligibility
50 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Chula Vista, California + 19 more
Conditions
Alzheimer's Disease
Interventions
Aducanumab (BIIB037), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 50 more
Conditions
Alzheimer's Disease
Interventions
levetiracetam
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Conditions
Alzheimer's Disease
Interventions
Cognitive Training
Behavioral
Lead sponsor
University of Kansas
Other
Eligibility
60 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Terminated Not applicable Interventional Results available

Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's

NCT02769000
Conditions
Alzheimer's Disease
Interventions
10 GY in 5 daily fractions, 20 GY in 10 daily fractions
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
55 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Alzheimer's Disease
Interventions
ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg, Placebo- Phosphate buffered saline (PBS)
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
40
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 17 more
Conditions
Alzheimer's Disease
Interventions
Tilavonemab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
57 Years to 88 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
32
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 27 more
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
E2814, Lecanemab, Matching Placebo (E2814)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Conditions
Alzheimer Disease
Interventions
Genetic Testing
Genetic
Lead sponsor
Baylor Research Institute
Other
Eligibility
40 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Completed No phase listed Observational Accepts healthy volunteers

Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)

NCT03718494
Conditions
Alzheimer Dementia
Interventions
Brain Magnetic Resonance Imaging (MRI), F-18 Florbetapir Positron Emission Tomography (PET) Imaging, F-18 AV-1451 Positron Emission Tomography (PET) Imaging, Neuropsychological Testing
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
49 Years to 72 Years · Female only
Enrollment
299 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 3 more
Conditions
Early Alzheimer's Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Withdrawn Not applicable Interventional Accepts healthy volunteers

Reminiscence, Anxiety and Early Alzheimer's Disease

NCT02319681
Conditions
Alzheimer's Disease
Interventions
Simple Reminiscence (SR), Attention Control (AC)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Depression, Pain, Cognitive Impairment
Interventions
PATH-Pain
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
White Plains, New York